Here, we demonstrated that RNF5 inhibition suppresses PEL xenograft tumor growth and oncogenic KSHV lytic replication through increased EphA3 and EphA4 levels and decreased downstream pathways. The gene discussed is EPHA4; the disease is neoplasm.